Inflammation and Brain Disorders: A series of Articles
Neuroinflammation, either directly occurring in the brain from microglial activation or indirectly from peripherally generated immune modulators, is becoming apparent as a component of a number of brain disorders, including Alzheimer’s disease, depression, bipolar disorder and schizophrenia.
In familial disease associated with PSEN-1 mutations, symptomatic carriers show progressive loss of cortical thickness in areas involved in Alzheimer’s Disease (AD). In contrast, in asymptomatic carriers increased thickness suggests that inflammatory processes or reactive neuronal hypertrophy may be involved in the preclinical phase. Further evidence of a non-linear trajectory in neuroanatomical changes comes from studies relating cortical thickness to beta-amyloid levels in CSF. The context for such studies is growing interest in diagnosing early stages of AD through biomarkers rather than clinical signs and symptoms.
This article addresses the blood-borne factors related to inflammation and aging, heterogeneity within schizophrenia and the hypothesis that people with schizophrenia experience pathological aging
This article investigates Major Depressive Disorder (MDD) and the relationship between inflammatory markers and treatment response and resistance.